Int J Stomatol

Inter J Stomatol ›› 2016, Vol. 43 ›› Issue (3): 366-370.doi: 10.7518/gjkq.2016.03.025

Previous Articles    

Analysis of the safety of thalidomide in the treatment of oral mucosal diseases

Song Tao, Wang Jiongke, Wen Jing, Chen Qianming, Zeng Xin   

  1. State Key Laboratory of Oral Diseases, Dept. of Oral Medcine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China) This study was supported by Natural Science Foundation of China(81472533)and Nonprofit Industry Research Sepecific Fund of National Health and Family Planning Commission of China(201502018).
  • Received:2015-08-22 Revised:2015-12-11 Online:2016-05-01 Published:2016-05-01

RichHTML

5

PDF (PC)

640

Abstract: Thalidomide has been on the market for more than 60 years. It is currently used for the treatment of inflammatory and autoimmune diseases, including a variety of oral mucosal diseases. Due to its serious teratogenic effect, many oral medicine specialists are very cautious about the safety of thalidomide in the clinical application. To clarify its effect, especially on patients of childbearing age and children, we sum up the pharmacokinetics, mechanism and clinical studies of thalidomide. We hope that this review could provide oral medicine specialists with more comprehensive information on the clinical safety and effectiveness of thalidomide for the treatment of oral mucosal diseases.

Key words: thalidomide, drug safety, oral mucosal diseases, child-bearing period woman, pediatrics, thalidomide, drug safety, oral mucosal diseases, child-bearing period woman, pediatrics

CLC Number: 

  • R 781.5

TrendMD: 
[1] Teo SK, Colburn WA, Tracewell WG, et al. Clinical pharmacokinetics of thalidomide[J]. Clin Pharmacokinet, 2004, 43(5):311-327.
[2] Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents[J]. Nat Rev Cancer, 2004, 4(4):314-322.
[3] Friderichs E. Studies on the CNS activity profile of thalidomide analogs(author’s transl)[J]. Arzneimittelforschung, 1982, 32(6):613-620.
[4] Youdim MB, Ashkenazi R. Serotonergic involvement in pharmacological action of the anxiolytic-sedatives thalidomide and supidimide[J]. Eur J Pharmacol, 1985, 119(1/2):39-46.
[5] Therapontos C, Erskine L, Gardner ER, et al. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation[J]. Proc Natl Acad Sci U S A, 2009, 106(21):8573-8578.
[6] Wines NY, Cooper AJ, Wines MP. Thalidomide in dermatology[J]. Australas J Dermatol, 2002, 43(4):229-240.
[7] Karim MY, Ruiz-Irastorza G, Khamashta MA, et al. Update on therapy—thalidomide in the treatment of lupus[J]. Lupus, 2001, 10(3):188-192.
[8] Lin AY, Brophy N, Fisher GA, et al. Phase Ⅱ study of thalidomide in patients with unresectable hepatocellular carcinoma[J]. Cancer, 2005, 103(1):119-125.
[9] Eriksson T, H?glund P, Turesson I, et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis[J]. J Pharm Pharmacol, 2003, 55(12):1701-1706.
[10] Shiah HS, Chao Y, Chen LT, et al. Phase Ⅰ and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2006, 58(5):654-664.
[11] Yang CS, Kim C, Antaya RJ. Review of thalidomide use in the pediatric population[J]. J Am Acad Dermatol, 2015, 72(4):703-711
[12] Franks ME, Macpherson GR, Figg WD. Thalidomide [J]. Lancet, 2004, 363(9423):1802-1811.
[13] Meganathan K, Jagtap S, Wagh V, et al. Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells[J]. PLoS One, 2012, 7(8):e44228.
[14] Offidani M, Corvatta L, Marconi M, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy[J]. Eur J Haematol, 2004, 72(6):403-409.
[15] Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients[J]. J Invest Dermatol, 2002, 119(5):1020-1026.
[16] Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study[J]. J Pediatr, 2004, 145(6):856-857.
[17] Nakamura K, Matsuzawa N, Ohmori S, et al. Clinical evidence of pharmacokinetic changes in thalidomide therapy[J]. Drug Metab Pharmacokinet, 2013, 28(1):38-43.
[18] Vianna FS, Lopez-Camelo JS, Leite JC, et al. Epidemiological surveillance of birth defects compatible with thalidomide embryopathy in Brazil[J]. PLoS One, 2011, 6(7):e21735.
[19] Schuler-Faccini L, Soares RC, de Sousa AC, et al. New cases of thalidomide embryopathy in Brazil[J]. Birth Defects Res A Clin Mol Teratol, 2007, 79(9):671-672.
[20] Cheng S, Murphy R. Refractory aphthous ulceration treated with thalidomide: a report of 10 years’ clinical experience[J]. Clin Exp Dermatol, 2012, 37(2):132-135.
[21] Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group[J]. N Engl J Med, 1997, 336(21):1487-1493.
[22] Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus[J]. Int J Dermatol, 2000, 39(3):218-222.
[23] Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis[J]. Arch Dermatol, 1990, 126(7):923-927.
[24] Lazzerini M, Martelossi S, Magazzù G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial[J]. JAMA, 2013, 310(20):2164-2173.
[25] Samsoen M, Grosshans E, Basset A. Thalidomide in the treatment of discoid lupus erythematosus (D.L.E.)(author’s transl)[J]. Ann Dermatol Venereol, 1980, 107(6):515-523.
[26] Yasui K, Kobayashi N, Yamazaki T, et al. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation[J]. Curr Pharm Des, 2005, 11(3):395-401.
[27] Rigante D, La Torre F, Calcagno G, et al. Clinical response to thalidomide and colchicine in two siblings with Behcet’s disease carrying a single mutated MEFV allele[J]. Rheumatol Int, 2012, 32(6):1859-1860.
[28] Hello M, Barbarot S, Bastuji-Garin S, et al. Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis[J]. Medicine: Baltimore, 2010, 89(3):176-182.
（本文采编 王晴）
[1] Zhu Lili1, Zeng Xin1, Li Chunjie1, Tan Dan1, Chen Qianming1, Wang Zhi2.. Efficacy and safety of thalidomide treatment for acquired immune deficiency syndrome-related recurrent aphthous ulcer: A systematic review [J]. Inter J Stomatol, 2012, 39(5): 572-574.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .